Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

CAPS Rating: 3 out of 5

A biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions.

Results 1 - 20 of 45 : 1 2 3 Next »

Recs

0
Member Avatar AllTooFoolish (79.86) Submitted: 4/4/2016 4:05:29 PM : Outperform Start Price: $145.98 ALXN Score: -5.78

Based on benchmark Investing math, this stock looks to be about 24% below its Downside price. It should do nicely over the next few years. That said, there is a huge reliance on Solaris right now. If things go well for Solaris or the pipeline, we will all smile. If not, then at least I warned you.

Recs

0
Member Avatar CMFMLove (< 20) Submitted: 3/16/2016 10:42:40 PM : Outperform Start Price: $130.56 ALXN Score: +4.68

ALXN hit a 52 week low, but the future is very bright. there's a strong pipeline with 2018 looking to be a pivotal year

Recs

0
Member Avatar andytraylor (42.16) Submitted: 10/29/2015 5:10:33 PM : Outperform Start Price: $176.36 ALXN Score: -19.96

Historically grown cash flow 50%+ a year yet trades at only 43 times cash flow

Recs

0
Member Avatar Charlotte49er (52.35) Submitted: 10/22/2015 10:37:45 PM : Outperform Start Price: $168.24 ALXN Score: -17.04

Stellar growth

Recs

0
Member Avatar murphydevani (71.12) Submitted: 8/26/2015 1:15:53 AM : Underperform Start Price: $170.72 ALXN Score: +26.05

Target $163 - $161 - $160

Recs

0
Member Avatar marsuculix (< 20) Submitted: 8/25/2015 5:39:25 AM : Outperform Start Price: $171.82 ALXN Score: -24.74

PDUFA on Sep 8 of former GEVA drug sebelipase alfa - indication LAL deficiency under BTD...

Recs

0
Member Avatar TMFTypeoh (77.50) Submitted: 8/17/2015 2:30:36 PM : Outperform Start Price: $190.37 ALXN Score: -25.16

Expensive, but high quality.

Recs

0
Member Avatar jdkosmicki (56.83) Submitted: 7/2/2015 8:09:20 PM : Outperform Start Price: $183.24 ALXN Score: -24.54

Forward p/e of 14. Also, people get diseases no matter what happens in Greece.

Recs

0
Member Avatar andrewtraylor (42.55) Submitted: 4/16/2015 5:06:12 PM : Outperform Start Price: $182.00 ALXN Score: -22.44

Good ROE, profit margins and growth

Recs

0
Member Avatar Juggernaut0609 (90.57) Submitted: 4/1/2015 11:44:17 AM : Outperform Start Price: $168.26 ALXN Score: -17.78

Huge growth, no debt, lots of cash.

Recs

1
Member Avatar Tophinater (< 20) Submitted: 10/24/2014 10:13:29 AM : Outperform Start Price: $187.36 ALXN Score: -31.51

Sure, why not?

Recs

0
Member Avatar pchop123 (80.71) Submitted: 7/13/2014 6:55:12 PM : Outperform Start Price: $164.32 ALXN Score: -19.92

upside in price very likely

Recs

1
Member Avatar BigFatBEAR (29.40) Submitted: 7/9/2014 4:22:34 PM : Outperform Start Price: $161.62 ALXN Score: -19.78

Too rich for my real cash at this level, but loved enough by informed folks, such as zzlangerhans, to make me a watcher. Low beta, which could be quite handy in a selloff, but I'm guessing this thing will kiss $100 someday in the next year or two, what with biotech being volatile and all.

Appears to be one of the best-of-breed in the sector, so if you're going to own individual stocks instead of IBB, might as well go this route.

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/5/2014 9:35:59 AM : Outperform Start Price: $155.11 ALXN Score: -20.94

13 classic growth stocks (Sterman).

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/7/2014 10:51:40 AM : Outperform Start Price: $164.85 ALXN Score: -25.40

BUY@ 165 1YR EPS 130% 2YR EPS 200% TP 188

Recs

0
Member Avatar Dudeone (92.59) Submitted: 2/12/2014 6:35:18 PM : Outperform Start Price: $174.23 ALXN Score: -34.33

Soliris continuing to grow and good products in pipeline e.g. asfotase

Recs

0
Member Avatar billyw10 (< 20) Submitted: 1/3/2014 6:26:30 PM : Outperform Start Price: $131.66 ALXN Score: -7.09

orphan drug alxn

Recs

0
Member Avatar CarlosDK (25.75) Submitted: 1/10/2013 8:12:04 AM : Underperform Start Price: $100.68 ALXN Score: +2.86

expensive on all valuations

Recs

0
Member Avatar ayuddha (29.51) Submitted: 7/15/2012 5:18:50 PM : Outperform Start Price: $96.87 ALXN Score: -9.13

It was picked by www.hechtsoft.de Trade Alerts.

Recs

1
Member Avatar danrifenburgh (< 20) Submitted: 12/19/2011 1:25:55 PM : Outperform Start Price: $67.44 ALXN Score: +35.00

After a 60% run-up, this volatile stock seems due for a fall. TM P/E of 82.96 with expected earnings growth of 31.54% taking it to a forward P/E of 38.81 next year. ALXN also trades at a premium to S&P500 TTM P/E. The PEG stands at 2.24, this could suggest some overvaluation. The Price/Book is 11.62.

Results 1 - 20 of 45 : 1 2 3 Next »

Featured Broker Partners